Eloralintide has Phase 2 RCT-grade evidence for Obesity. Off-label / exploratory data exists for 4 additional indications (Overweight; Pharmacokinetic / healthy volunteer studies).
Data last updated
Evidence shape
Eloralintide has Phase 2 RCT-grade evidence for Obesity. Off-label / exploratory data exists for 4 additional indications (Overweight; Pharmacokinetic / healthy volunteer studies).
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Obesity
−9.0 percent change6 studies · 2 completed
Overweight
5 studies · 1 completed
Pharmacokinetic / healthy volunteer studies
1 study
Sleep Apnea, Obstructive
1 study
3 completed study rows are present, but endpoint pass/fail classification is still pending.
Human evidence
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Anecdotal side effects
price offers can be sorted by column
How ELORALINTIDE is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
According to the trial documentation, eloralintide was administered subcutaneously at 1 mg once weekly across the three research studies evaluated overall.
According to a single source, clinicians report eloralintide dosing at 1 mg subcutaneously each day, with no cycling protocol specified or recorded.
Community reports typically use 6 mg subcutaneously, with individual amounts ranging from about 0.5 mg to 12.5 mg, and frequency was not specified in the anecdotal notes.